XML 15 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Operating activities:    
Net loss $ (113,629) $ (106,769)
Adjustments to reconcile net loss to net cash used for operating activities:    
Stock-based compensation expense 22,727 23,088
Depreciation and amortization 1,473 1,366
Amortization of debt discount 785 645
Amortization of premium (accretion of discount) on short-term investments 178 (82)
Impairment of property and equipment 190 53
Change in operating assets and liabilities:    
Accounts receivable (765) 2,377
Inventory (895) (16,474)
Prepaid expenses and other assets (1,783) 10,136
Accounts payable 10,717 15,700
Accrued clinical and manufacturing liabilities (26,055) (4,441)
Accrued payroll and employee liabilities 84 (4,055)
Other accrued liabilities 2,043 (11,756)
Net cash used for operating activities (104,930) (90,212)
Investing activities:    
Purchases of short-term investments (62,046) (66,915)
Maturities and sales of short-term investments 98,500 166,825
Purchases of property and equipment (1,101) (3,687)
Net cash provided by investing activities 35,353 96,223
Financing activities:    
Net proceeds from convertible note financing 148,982  
Proceeds from issuance of common stock under equity incentive plan 5,101 1,309
Proceeds from purchases under the Employee Stock Purchase Plan 1,529 1,507
Proceeds from warrant exercises   3
Net cash provided by financing activities 155,612 2,819
Net increase in cash and cash equivalents 86,035 8,830
Cash and cash equivalents at beginning of year 105,138 71,898
Cash and cash equivalents at end of period $ 191,173 $ 80,728